Random l-colourable structures with a pregeometry

We study finite $l$-colourable structures with an underlying pregeometry. The probability measure that is used corresponds to a process of generating such structures (with a given underlying pregeometry) by which colours are first randomly assigned to all 1-dimensional subspaces and then relationships are assigned in such a way that the colouring conditions are satisfied but apart from this in a random way. We can then ask what the probability is that the resulting structure, where we now forget the specific colouring of the generating process, has a given property. With this measure we get the following results: 1. A zero-one law. 2. The set of sentences with asymptotic probability 1 has an explicit axiomatisation which is presented. 3. There is a formula $\xi(x,y)$ (not directly speaking about colours) such that, with asymptotic probability 1, the relation "there is an $l$-colouring which assigns the same colour to $x$ and $y$" is defined by $\xi(x,y)$. 4. With asymptotic probability 1, an $l$-colourable structure has a unique $l$-colouring (up to permutation of the colours).Comment: 35 page

Accumulation of natural killer cells after hepatic artery embolisation in the midgut carcinoid syndrome.

Eleven patients with disseminated midgut carcinoid tumour disease were subjected to hepatic artery embolisation. In six patients, lymphocytosis with a predominance of NK cells occurred and the cytotoxic activity of isolated lymphocytes increased. A relation between NK cell accumulation and subsequent radiological and biochemical response was observed, and it is suggested that anti-tumour mechanisms other than ischaemia may contribute to the therapeutic response in these patients

Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour

Somatostatin receptor (sstr)-mediated radiation therapy is a new therapeutic modality for neuroendocrine (NE) tumours. High expression of sstr in NE tumours leads to tumour-specific uptake of radiolabelled somatostatin analogues and high absorbed doses. In this study, we present the first optimised radiation therapy via sstr using [177Lu-DOTA0-Tyr3]-octreotate given to nude mice xenografted with the human midgut carcinoid GOT1. The tumours in 22 out of 23 animals given therapeutic amounts showed dose-dependent, rapid complete remission. The diagnostic amount (0.5 MBq [177Lu-DOTA0-Tyr3]-octreotate) did not influence tumour growth and was rapidly excreted. In contrast, the therapeutic amount (30 MBq [177Lu-DOTA0-Tyr3]-octreotate) induced rapid tumour regression and entrapment of 177Lu so that the activity concentration of 177Lu remained high, 7 and 13 days after injection. The entrapment phenomenon increased the absorbed dose to tumours from 1.6 to 4.0 Gy MBq−1 and the tumours in animals treated with 30 MBq received 120 Gy. Therapeutic amounts of [177Lu-DOTA0-Tyr3]-octreotate rapidly induced apoptosis and gradual development of fibrosis in grafted tumours. In conclusion, human midgut carcinoid xenografts can be cured by receptor-mediated radiation therapy by optimising the uptake of radioligand and taking advantage of the favourable change in biokinetics induced by entrapment of radionuclide in the tumours